Sound View Wealth Advisors Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Sound View Wealth Advisors Group’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$409K	Buy	+3,682	New	+$333K	0.03%	313

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sound View Wealth Advisors Group's RYTM Position: Q2 2026 in Review

Sound View Wealth Advisors Group opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 3,682 shares worth $409K. The stake represents 0.03% of the portfolio and ranks #313 among its holdings.

303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Sound View Wealth Advisors Group held 3,682 shares of Rhythm Pharmaceuticals worth $409K as of Q2 2026.
Rhythm Pharmaceuticals was a new Sound View Wealth Advisors Group position in Q2 2026.
Rhythm Pharmaceuticals made up 0.03% of Sound View Wealth Advisors Group's portfolio in Q2 2026, its #313 holding.
303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Sound View Wealth Advisors Group's 13F filing for Q2 2026, filed 11 Aug 2026.